slides · global inventory
Disclaimer
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 41,127
Current window 33,031-33,060
Pages 1,371
Rows per page 30
Component
33,031-33,060 of 41,127
17
The chart highlights a significant spike in charge-offs for the S&P index during the 2008-2012 period compared to NYCB.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
18
The chart uses a dashed line to represent the peer median of 0.55%.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
20
The slide highlights NYCB's relative capital position using two different metrics (Adjusted vs Reported).New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
37
The chart illustrates the transition from $2,088M in 2023 to $2,353M in 2024.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · Guidance1 hit
02
Nuvalent | Investor Presentation Deck | 41 slidesNuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
15
The slide uses a split-screen layout to contrast in vitro IC50 data with in vivo tumor regression data.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
16
Includes technical definitions of selectivity index and experimental conditions for Wistar Han rats.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
19
Data cut-off: 8 Aug 2023. Includes detailed breakdown of resistance mutations and prior treatment history.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
22
Includes two patient case studies with MRI scans showing tumor reduction.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
23
Data cut-off: 8 Aug 2023. N=93 patients.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
24
The slide uses a three-column layout to segment the market by treatment line (3L+, 2L, 1L) and define the specific clinical opportunity for each.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
29
The slide uses three distinct chart types to demonstrate competitive advantages in potency, PK, and selectivity.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
30
The slide presents a clinical trial snapshot including patient eligibility criteria and a breakdown of patient enrollment by dose cohort.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
31
The slide presents two side-by-side tables detailing patient characteristics and treatment history for a clinical trial cohort.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
33
Includes clinical trial data from ARROS-1 Phase 1 study.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
35
The chart shows pharmacokinetic curves for four different dose levels against four target efficacy thresholds.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
02
Nuvalent | Investor Presentation Deck | 42 slidesNuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
15
The slide presents two distinct scientific data sets: an IC50 dot plot for in vitro activity and a bar chart for in vivo tumor regression.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
18
Data cut-off: 8 Aug 2023. Includes detailed breakdown of prior ALK TKI therapies.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
20
Data cut-off: 8 Aug 2023. Includes detailed breakdown of response by mutation type and prior treatment history.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
21
Clinical trial data (ALKove-1) showing efficacy of NVL-655 in NSCLC patients.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
22
Swimmer plot visualization of clinical trial patient outcomes.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
23
Includes before/after MRI scans for two specific patient cases.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
30
Includes specific pharmacological data points for NVL-520 vs competitors like Crizotinib, Entrectinib, Lorlatinib, Taletrectinib, and Repotrectinib.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
31
The slide presents a summary of a clinical trial, including patient eligibility criteria and a breakdown of patient enrollment by dose cohort.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
32
Data presented in two side-by-side tables summarizing patient characteristics and treatment history.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
34
Includes clinical trial data (ARROS-1 Phase 1) with specific patient subgroup outcomes.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
36
The chart shows pharmacokinetic data (NVL-520 concentration over time) compared against target efficacy thresholds for different ROS1 variants.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
38
The slide outlines a multi-cohort clinical trial design with specific patient segments based on prior treatment history.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
02
Nuvectis Pharma | Investor Presentation Deck | 25 slidesNuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations 1 hit